DoP invites applications under PLI scheme for manufacturing KSMs, drug intermediates, APIs

Cyclohexanediacetic acid, commonly known as 1,1 cyclohexanediacetic acid or cyclohexane diacetic acid, is mostly used as a precursor to the antidepressant gabapentin.

Artesunate is an artemisinin derivative produced by reducing the lactone carbonyl group of artemisinin to form the hemisuccinate ester of lactol. It is commonly used in the treatment of malaria as the sodium salt. It possesses antimalarial properties.

This notice came in continuation to the Department's Notice of even number dated 30.04.2021, where applications were invited for the products included Neomycin, Gentamycin, Clindamycin, Tetracycline, Streptomycin, Vitamin B1etc.

In light of the foregoing, the Department of Pharmaceuticals recently issued a revised notification inviting applications under the Production Linked Incentive (PLI) Scheme for Promoting Domestic Manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates, and Active Pharmaceutical Ingredients (APIs) in the Country for the remaining slots/quantities for the following eligible products:

Further, the notice stated that other terms and conditions mentioned in the previous notice dated 30.04.2021 should remain unchanged.

Earlier this month, the Medical Dialogues team reported that the Department of Pharmaceuticals (DoP) had issued operational guidelines for the Production Linked Incentive (PLI) Scheme for pharmaceuticals with an approved outlay of Rs 15,000 crore, where the Ministry of Chemicals and Fertilizers had categorized the eligible products into three categories, which include formulations, biopharmaceuticals, active pharmaceutical ingredients, key starting materials, drug intermediates, in-vitro diagnostic medical devices, etc.

To view the official notice, click the link below: